Strides Pharma Science Limited has completed its regulatory compliance obligations by submitting the mandatory certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the necessary documentation through its registrar and share transfer agent, KFin Technologies Limited.

Regulatory Compliance Framework

The certificate submission forms part of the company's ongoing compliance with securities market regulations. Under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, companies are required to provide periodic certifications regarding the dematerialization and rematerialization of securities during specified quarters.

Certificate Submission Details

KFin Technologies Limited, acting as the registrar to the issue and share transfer agent for Strides Pharma Science Limited, certified that all required details of securities transactions have been properly reported. The certification covers the period ending March 31, 2026, and confirms compliance with regulatory requirements.

Depository Communications

The certificates were formally submitted to both major depositories in India. KFin Technologies Limited addressed separate communications to National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL), confirming that details of securities dematerialized and rematerialized during the quarter have been furnished to all stock exchanges where the company's shares are listed.

Stock Exchange Notifications

Strides Pharma Science Limited's Company Secretary and Compliance Officer, Manjula Ramamurthy, formally notified both the National Stock Exchange of India Limited and The BSE Limited about the certificate submission. The company trades on NSE under the scrip code STAR and on BSE under scrip code 532531.

Corporate Information

The company maintains its corporate office at Strides House, Bilekahalli, Bannerghatta Road, Bengaluru, while its registered office is located at Cyber One, Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai. KFin Technologies Limited operates from its registered office in Mumbai and maintains operational facilities in Hyderabad.

Strides Pharma Science has filed a comprehensive regulatory disclosure under SEBI Regulation 30 regarding its strategic $12 million acquisition of branded generic pharmaceutical products from Sandoz across Sub-Saharan Africa. The formal disclosure, submitted to BSE and NSE on March 17, 2026, provides detailed transaction parameters and corporate guarantee arrangements for the deal announced earlier.

Transaction Structure and Parties

The acquisition involves multiple entities within the Strides group structure, with specific roles defined for regulatory compliance:

Portfolio Coverage and Market Impact

The transaction encompasses four key markets where Strides maintains established operations: Western Sahara (10 countries), Ghana, Nigeria, and Kenya. The portfolio includes multiple established brands across anti-infective, cardiovascular, and dermatology therapeutic segments, with several products individually recording annual sales exceeding $1 million.

The integration is expected to position Strides among the top five pharmaceutical companies in the Sub-Saharan Africa region by sales, and among the top two within its represented markets. The deal structure includes both fully acquired products and select products that Strides will continue to market through in-licensing arrangements.

Corporate Guarantee Framework

As part of the transaction structure, Strides Pharma Global Pte. Limited will provide corporate guarantees to Sandoz securing SPIAG's payment obligations:

Regulatory and Compliance Aspects

The disclosure confirms that the transaction with Sandoz does not constitute a related party transaction, with promoter groups having no interest in the deal. However, inter-company transactions between SPIAG and SPG are classified as related party transactions conducted at arm's length.

The transaction remains subject to customary closing conditions, including antitrust filings in applicable jurisdictions. Expected completion is targeted for the end of Q2 FY27 (September 30, 2026), with the arrangement also providing for yearly royalty payments based on a percentage of net sales for Distribution Products.

Strategic Alignment

The formal regulatory filing reinforces the strategic importance of this acquisition to Strides' 'in Africa for Africa' strategy. The transaction is designed to enhance market reach across key SSA markets, strengthen therapeutic leadership, and unlock cross-selling opportunities through deeper penetration of prescriber bases, pharmacies, clinics, and healthcare institutions.